苯扎贝特对肥胖患者2型糖尿病发病率的影响

作     者：Tenenbaum A. Motro M. Fisman E.Z. 潘闽 

作者机构：Cardiac Rehabilitation InstituteChaim Sheba Medical Center Tel-Hashomer 52621 Israel 

出 版 物：《世界核心医学期刊文摘(心脏病学分册)》 (Digest of the World Core Medical Journals(Cardiology))

年 卷 期：2006年第4期

页      面：51-52页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：苯扎贝特 型糖尿病 肥胖患者 发病率 

摘      要：Aims: To assess the effect of fibric acid derivative bezafibrate on incidence of type 2 diabetes in obese patients over a median 6.3 years follow-up period. Methods and results: The study sample comprised 339 non-diabetic obese patients(body mass index≥30.0 kg/m2) aged 42-74. Patients received either bezafibrate retard 400 mg(178 patients) or placebo(161 patients) once daily. Development of new diabetes was recorded in 98 patients: in 56(37.0%) from the placebo group vs. 42(27.1%) from the bezafibrate group,(P log-rank=0.01). The median time(interquartile range) until onset of new diabetes was significantly delayed in patients on bezafibrate when compared with those on placebo: 4.0(2.1-5.0) vs. 2.0(0.5-3.5) years, P=0.002. Multivariable anal ysis identified bezafibrate treatment as an independent predictor of reduced risk of new diabetes with hazard ratio(HR) 0.59[95%confidence interval(CI) 0.39-0.91]. Other significant variables associated with future overt type 2 diabetes in obese patients were triglycerides(50 mg/dL increment) with HR 1.15(95%CI 1.02-1.28) and fasting glucose(10 mg/dL increment) with HR 2.27(95%CI 1.83-2.81). Conclusion: Bezafibrate, when compared with placebo, reduced the incidence and delayed the onset of type 2 diabetes in obese patients over a long-term follow-up period.